Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

H. O'Donnell, Peter; I. Milowsky, Matthew; P. Petrylak, Daniel; J. Hoimes, Christopher; W. Flaig, Thomas; Mar, Nataliya; H. Moon, Helen; W. Friedlander, Terence; R. McKay, Rana; A. Bilen, Mehmet; Srinivas, Sandy; F. Burgess, Earle; Ramamurthy, Chethan; George, Saby; M. Geynisman, Daniel; Bracarda, Sergio; Borchiellini, Delphine; Geoffrois, Lionnel; Pablo Maroto Rey, Jose; Ferrario, Christiano; Carret, Anne-Sophie; Yu, Yao; Guseva, Maria; Homet Moreno, Blanca; E. Rosenberg, Jonathan

doi:10.1200/jco.22.02887

Public

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Shared by NobleBlocks on Sep 1, 2023 • 12:00 AM UTC

Authors:

Peter H. O'Donnell

Matthew I. Milowsky

Daniel P. Petrylak

Abstract

PURPOSE Patients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and significant need for improved therapies. Enfortumab vedotin (EV) and pembrolizumab (Pembro) individually have shown a surv...

Discussions